All In Biotech

Drug Trial Radar · NCT07579351

Corticosteroid Lumbar Epidural Analgesia for Radicular Pain 2

Corticosteroid Lumbar Epidural Analgesia for Radicular Pain (C.L.E.A.R) 2 - A Randomized, Double-blind, Active Comparator and Placebo-controlled, Multicenter, Safety and Efficacy Trial of SP-102

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 755 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

755

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Nov 2028

Study completion Apr 2029

Sponsor

Lead sponsor
Semnur Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Syngene; Cromos Pharma LLC
First posted
May 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a research study of SP-102, an experimental medication designed to relieve pain in patients with moderate to severe sciatica (pain in the lower back, hips, buttocks and legs). SP-102, placebo (a medication that looks like SP-102 but does not contain any active ingredient), or an active comparator (dexamethasone sodium phosphate) is given once by the participant's healthcare professional. If a participant meets qualifications, each participant will have the option of receiving one supplemental open-label injection of SP-102, greater than four weeks and up to twenty weeks after their first injection. The purpose of the study is to measure how well a single injection of the experimental medication, SP-102, relieves pain versus placebo. The study will also measure how well SP-102 relieves pain versus an active comparator medication (dexamethasone sodium phosphate). The study will also investigate the side effects of SP-102.

Conditions

  • Lumbosacral Radicular Pain

Interventions

  • SP-102Drug

    One Injection

  • PlaceboDrug

    One injection

  • Dexamethasone Sodium Phosphate 10 MG/MLDrug

    One injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline to W4 in the mean NPRS average daily pain score.Time frame: Day 1 to week 4

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.